Attached files

CytoDyn Elects New President and CEO


Santa Fe, NM -- [DATE SLUG] -- The Board of Directors of CytoDyn, Inc. (Pink
Sheet:CYDY) has elected current director Kenneth J Van Ness President and CEO.
Mr. Van Ness succeeds Allen D Allen, current Chairman, President and CEO. Mr.
Allen will remain Chairman.

"I am honored to become President and CEO and to help move CytoDyn forward in
its evolution and development." said Mr. Van Ness. "The shareholders need to be
proud of what CytoDyn and Al Allen have accomplished so far in its development.
CytoDyn has pioneered, a unique monoclonal antibody, Cytolin(R), for the
treatment of HIV/ AIDS, and this product has tremendous potential." said Mr. Van
Ness.

"CytoDyn will continue to refine and develop a collaborative effort to move our
primary, one-of-a-kind drug, Cytolin(R), to the completion of its necessary
clinical trials. CytoDyn has reached a point in our business cycle where we need
to develop and evaluate all aspects of our business. I am looking forward to
interacting and developing investment banking and related PHARMA relationships"
comments Mr. Van Ness.

"I welcome this opportunity to work with my colleagues and Board and to lead
this Company successfully into the future. We have a lot to do, and I am
intensely focused on building shareholder value." said Mr. Van Ness.

"Mr. Van Ness will have my full support, and I am confident that Ken will
deliver a new era of growth for our shareholders." said Mr. Allen, Chairman and
founder of CytoDyn.

This announcement contains statements that are not historic facts but anticipate
future events and circumstances. All such forward-looking statements made by the
Company are necessarily estimates based upon current information and projections
and involve a number of risks and uncertainties, including but not limited to,
the failure of preliminary results from clinical studies to reflect the results
from more comprehensive studies, and an inability to enroll a sufficient number
of patients or to otherwise complete a study. There can be no assurance that
such risks and uncertainties, or other factors, will not affect the accuracy of
such forward-looking statements. It is impossible to identify all the factors
that could cause actual results to differ materially from those estimated by
CytoDyn. They include, but are not limited to, government regulation, managing
and maintaining growth, and the effects of adverse publicity, litigation,
competition, and other factors that may be identified from time to time in the
Company's announcements.

Source: CytoDyn
Contact: Corinne or Stacia (505) 988-5520